Mireille Vega

Chief Executive Officer @ VGAM biome

About

Mireille Vega, Chemist, PhD, is the founder of VGAM Biome and the creator of the One Human Skin™ framework — a science-based approach that connects skin biology, environmental exposure, and prevention across the lifespan. Trained as a chemist and grounded in microbiome and longevity science, her work bridges rigorous research with real-world application, reframing skincare as a pillar of human and planetary health. Mireille is also known as Dr. Mimi V., the name she uses for her educational and public-facing work, including speaking, teaching, and science translation for broader audiences. Through VGAM Biome, she applies the One Human Skin™ framework to product innovation and education, advancing a new standard for skin health rooted in biology, evidence, and prevention.

Country

Canada

City

Montreal

Industry

Biotechnology

Skill

Skin Care Products, Entrepreneurship, New Business Development, Immunology, Oncology, Pharmaceutical Industry, Clinical Development, Medical Affairs, Clinical Trials, Hematology, Biotechnology, Life Sciences, GCP, Drug Development, Dermatology, Medical Writing, Pharmacology, CRO, Infectious Diseases, Market Access

Experience

Chief Executive Officer

VGAM biome

2019-9 - Present · 7 yrs

Canada

VGAM Biome is a science-led skincare company founded on the One Human Skin™ framework, integrating skin microbiome research, environmental exposure science, and prevention-focused innovation to support long-term skin health.

Dr. Mimi V. — Speaking & Science Education (Platform)

https://www.drmimi.ca/onehumanskin

2015-5 - Present · 11 yrs 4 mos

Canada

Dr. Mimi V. is the educational and speaking platform of Mireille Vega, Chemist, PhD — translating skin microbiome and longevity science into accessible, actionable insights for diverse audiences. Speaking themes include: the One Human Skin™ framework (biology + environment + prevention), skin microbiome literacy, longevity-informed skincare, and myth-busting in wellness and skincare claims. Formats: Keynotes, panels, executive salons, and educational workshops. Audience fit: health & wellness organizations, innovation and sustainability forums, scientific and clinical communities, and founder/leadership audiences.

Consultant - Medical Director

Ionis Pharmaceuticals, Inc.

2021-4 - 2022-3 · 1 yr

California, United States

-Pre-launch medical direction for eplontersen asset -Cross-functional leadership within brand team

Global/US Medical Affairs

Ionis Pharmaceuticals, Inc.

2020-11 - 2021-4 · 6 mos

Massachusetts, United States

-Expert guidance on Medical Information transition to partners -Medical Affairs executive direction to leadership

Interim Medical Director, Medical Affairs Canada

Ionis Pharmaceuticals, Inc.

2019-12 - 2020-11 · 1 yr

Canada

Previously Akcea Therapeutics

Business Development Director

Axelys

2018-3 - 2019-9 · 1 yr 7 mos

Montreal, Canada Area

-Previously Gestion Univalor -Evaluation of technical feasibility and commercial potential of new technologies -Development of technology transfer strategies including IP protection and licensing

Head, Medical Affairs, Oncology and Hematology

AbbVie

2015-8 - 2017-5 · 1 yr 10 mos

Western Europe and Canada

• Builds oncology medical leadership within the organization including hiring and coaching of high performance teams • Develops collaborative network within Global, Regional and Canadian teams as well as with key stakeholders for successful implementation of strategic and tactical plans • Leads pre-launch and launches phases for oncology and hematology and state of the art implementation both from a timeline and ethics and compliance perspective

Medical Advisor

Novartis

2014-7 - 2015-8 · 1 yr 2 mos

• scientific and clinical development expertise; immunology (rheumatology and dermatology) • Liaises and synergizes with national stakeholders and global biologics cross-functional teams

New Product Development Manager

Novartis

2012-6 - 2014-8 · 2 yrs 3 mos

Canada

• Development of Oncology Business Unit’s top pipeline pre-launch plans • Strategic direction for emerging pipeline indications in hematology, oncology and skin cancer • Management of launch projects and teams to optimize lifecycle